A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care
NCT00071799
·
clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
358
Enrollment
INDUSTRY
Sponsor class
Conditions
Myelodysplastic Syndromes
Interventions
DRUG:
Azacitidine
OTHER:
Physician Choice
Sponsor
Celgene